Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-06-10
2008-11-25
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S152000, C548S180000, C548S217000, C548S301700, C548S302700, C514S365000, C514S374000, C514S375000, C514S385000, C514S393000
Reexamination Certificate
active
07456204
ABSTRACT:
The present invention is directed to novel cyclohexylglycine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
REFERENCES:
patent: 4386090 (1983-05-01), Moinet et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6011155 (2000-01-01), Villhauer
patent: 6166063 (2000-12-01), Villhauer
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6432969 (2002-08-01), Villhauer
patent: 6699871 (2004-03-01), Edmondson et al.
patent: 7098239 (2006-08-01), Edmondson et al.
patent: WO 97/40832 (1997-11-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 00/34241 (2000-06-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/42262 (2001-06-01), None
patent: WO 01/42262 (2001-06-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 01/96295 (2001-12-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/076450 (2002-10-01), None
patent: WO 03/000180 (2003-01-01), None
patent: WO 03/000180 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 2005/002530 (2003-01-01), None
patent: WO 03/082817 (2003-10-01), None
patent: WO 2004/007468 (2004-01-01), None
patent: WO 2004/007468 (2004-01-01), None
patent: WO 2004/032836 (2004-04-01), None
patent: WO 2004/043940 (2004-05-01), None
patent: WO 2004/043940 (2004-05-01), None
patent: WO 2004/050022 (2004-06-01), None
patent: WO 2004/058266 (2004-07-01), None
patent: WO 2004/064778 (2004-08-01), None
patent: WO 2004/069162 (2004-08-01), None
patent: WO 2004/110436 (2004-12-01), None
patent: WO 2004/110436 (2004-12-01), None
patent: WO 2004/112701 (2004-12-01), None
patent: WO 2004/112701 (2004-12-01), None
patent: WO 2005/011581 (2005-02-01), None
patent: WO 2005/044195 (2005-05-01), None
patent: WO 2005/056003 (2005-06-01), None
patent: WO 2005/056013 (2005-06-01), None
patent: WO 2005/108382 (2005-11-01), None
patent: WO 2005-108382 (2005-11-01), None
patent: WO2005/116029 (2005-12-01), None
patent: WO 2005/116029 (2005-12-01), None
patent: WO 2005/123685 (2005-12-01), None
J. J. Holst, “Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors”, Expert Opin. Emerg. Drugs, vol. 9(1) pp. 155-166(2004).
C. F. Deacon, et al., “Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?”, Expert Opin. Investig. Drugs, vol. 13(9) pp. 1091-1102( 2004).
K. Augustyns et al., “Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes”, Expert Opin. Ther. Patents, vol. 13(4), pp. 499-510(2003).
Novartis AG: WO0034241, “Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus”, Exp. Opin. Ther. Patents, vol. 10(12), pp. 1937-1942 (2000).
O. J. Orucker, “Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes”, Exp. Opin Invest. Drugs, vol.12, pp. 87-100 (2004).
T. P. Vahl & D. A. D'Alessio, “Gut peptides in the treatment of diabetes mellitus” Exp. Opin. Invest. Drugs, vol. 13, pp. 177-188 (2004).
L. B. Knudsen, “Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes”, J. Med. Chem, vol. 47, pp. 4128-4134 (2004).
A. E. Weber, “Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes”, J. Med. Chem, vol. 47, pp. 4135-4141 (2004).
J. J. Holst and C. F. Deacon, “Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus”, Curr. Opin Pharmacology, vol. 4, pp. 589-596 (2004).
C. F. Deacon, “Perspectives in Diabetes—Therapeutic Strategies Based on Glucagon-Like Peptide 1”, Diabetes, vol. 53, pp. 2181-2189 (2004).
K. Augustyns, et al., “Inhibitors of proline-specific dipeptidyl peptidase: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes”, Expert Opin. Ther. Patents, vol. 15(10), pp. 1387-1407 (2005).
Hans-Ulrich Demuth, et al., “Type 2 diabetes—Therapy with dipetidyl peptidase IV inhibitors”, Biochimica et Biophysica Acta, vol. 1751, pp. 33-44 (2005).
Augustyns, K. et al., “Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes” , Expert Opin. Ther. Patents, vol. 13, No. 4, pp. 499-510, 2003.
Augustyns, K. et al., “Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes”, Expert Opin. Ther. Patent, vol. 15, No. 10, pp. 1387-1407, 2005.
Deacon, C. F., “Perspectives in Diabetes—Therapeutic Strategies Based on Glucagon-Like Peptide 1”, Diabetes, vol. 53, pp. 2181-2189, 2004.
Deacon, C. F. et al., “Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?”, Expert Opin. Investig. Drugs, vol. 13, No. 9, pp. 1091-1102, 2004.
Demuth, H. U. et al., “Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors”, Biochimica et Biophysica Acta, vol. 1751, pp. 33-44, 2005.
Drucker, D. J., “Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes”, Expert Opin. Investig. Drugs, vol. 12, No. 1, pp. 87-100, 2003.
Holst, J. J., “Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors”, Expert Opin. Emerg. Drugs, vol. 9, No. 1, pp. 155-166, 2004.
Holst, J. J. et al., “Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus”, Current Opinion Pharmacology, vol. 4, pp. 589-596, 2004.
Knudsen, L. B., “Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes”, J. Med. Chem, vol. 47, pp. 4128-4134, 2004.
Novartis AG: WO0034241—“Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus”, Exp. Opin. Ther. Patents, vol. 10, No. 12, pp. 1937-1942, 2000.
Vahl, T. P. et al., “Gut peptides in the treatment of diabetes mellitus”, Expert Opin. Investig. Drugs, vol. 13, No. 3, pp. 177-188, 2004.
Weber, A. E., “Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes”, J. Med. Chem., vol. 47, pp. 4135-4141, 2004.
Edmondson Scott D.
Mastracchio Anthony
Parmee Emma R.
Durette Philippe L.
Fitch Catherine D.
Merck & Co. , Inc.
Shameem Golam M
LandOfFree
Cyclohexylglycine derivatives as dipeptidyl peptidase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclohexylglycine derivatives as dipeptidyl peptidase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclohexylglycine derivatives as dipeptidyl peptidase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4051622